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Background
Tocilizumab is effective in treating sJIA in a phase III Jap-
anese study. Before the worldwide pivotal trial, 4 patients
were admitted to the compassionate use programme
available in 2006 at one UK centre.
Methods
Each patient was assessed clinically before dosing and lab-
oratory markers recorded. The dose was 8 mg/kg fort-
nightly iv. All had steroids and methotrexate concurrently.
The follow up period vary from 1 year to 18 months.
Results
In 3 patients CRP returned to normal after the first dose.
2/4 patients were below 30 kg and only had transient low-
ering of CRP between doses. Active joint counts decreased
partially in 2 and not in the 2 patients with body weight
<30 kg after 3 doses. These 2 patients were given 12 mg/
kg on the basis that pharmacokinetic modelling predicts
underexposure to the drug if given at 8 mg/kg, when the
body weight is <30 kg. The higher dose led to improve-
ments in clinical and laboratory markers. All were able to
reduce steroid therapy. There were no significant side
effects, apart from one with transient urticarial rash.
None are able to discontinue steroid therapy completely.
One has significant growth retardation on 5 mg pred-
nisolone daily. One still had 22 active joints (decreased
from 32) after one year with a normal CRP. She is now in
remission after a bone marrow allograft.
Conclusion
Multiple dosing of tocilizumab has greatly improved the
global disease activity of severe sJIA, but their arthritis
requires concurrent steroids and methotrexate. PK/PD
strategies to optimize dosing in sJIA may be indicated.
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